Form 4: Neurogene CFO Sells Shares Under 10b5-1 Plan

Neurogene Inc.'s President and CFO, Christine Mikail Cvijic, sold 4,800 shares of common stock for approximately $25.11 per share under a pre-arranged 10b5-1 plan.

Summary

• Christine Mikail Cvijic, President and CFO of Neurogene Inc., disposed of 4,800 shares of common stock.
• The transaction occurred on February 27, 2026, at a weighted average price of $25.1096 per share.
• The shares were sold in multiple transactions with prices ranging from $25.00 to $25.325.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.
• Following the transaction, Christine Mikail Cvijic directly beneficially owns 109,843 shares.
• The shares sold were held jointly by Christine Mikail Cvijic and her spouse, David Cvijic.
• Remaining beneficial ownership includes 21,269 restricted stock units (RSUs) from a March 13, 2024 grant, 20,300 RSUs from a March 26, 2025 grant, and 22,000 RSUs from a February 20, 2026 grant, all with annual vesting schedules.
• Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine insider transaction conducted under a pre-arranged 10b5-1 plan, which typically minimizes its interpretative impact on company fundamentals or future prospects.

Negatives

• An insider, the President and CFO, sold a portion of their common stock holdings, which could be perceived negatively by some investors, although it was pre-scheduled.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the pre-scheduled nature of the transaction and the vesting schedules of restricted stock units.

Industry Context

StockSavvy.ai notes that insider sales, particularly those executed under a Rule 10b5-1 plan, are common and do not necessarily indicate a negative outlook for the company. These plans allow insiders to sell shares at pre-determined times or prices to avoid accusations of trading on material non-public information. In the biotechnology sector, such sales can be part of personal financial planning, especially for executives with significant equity compensation.

Related Party Transactions

• Shares sold and a portion of remaining shares are held jointly by the reporting person and her spouse, David Cvijic.

Stakeholder Impact

• Shareholders may observe a slight increase in the public float due to the sale, but the impact is minimal given the small number of shares relative to total outstanding shares.
• The transaction itself does not directly impact employees, customers, suppliers, or creditors, as it is a personal financial transaction of an executive.

Next Steps

• Annual vesting installments for restricted stock units are scheduled for March 13, 2027, March 26, 2027, February 20, 2027, and subsequent years.

Key Dates

Recommendation

This Form 4 filing reports a pre-scheduled insider sale under a 10b5-1 plan, which is a routine event for executives managing their personal finances. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific transaction.

Keywords

Neurogene Inc., NGNE, Form 4, Insider Sale, Christine Mikail Cvijic, 10b5-1 Plan, Common Stock, Officer Transaction, Biotechnology, Gene Therapy